Pipeline        AIM Biologicals         Macimorelin Tx         AEZS-150         Macimorelin Dx        Vaccine Platform

Innovative, Salmonella-Based Vaccine Platform
 

Potential application across multiple coronavirus types, including COVID-19 (SARS-CoV-2)

Orally active live-attenuated bacterial vaccine based on
the salmonella typhi Ty21a carrier strain

x2

Dual-Antigens may offer lower likelihood of evolution of resistant viral mutants

Potential application across multiple coronavirus types, including COVID-19 (SARS-CoV-2) and Chlamydia trachomatis

Active live-attenuated bacterial vaccine based on
the salmonella typhi Ty21a carrier strain

x2

Dual-antigens may offer lower likelihood of evolution of resistant viral mutants

We are currently conducting pre-clinical research on a potential oral vaccine for COVID-19 (SARS-CoV-2) and Chlamydia trachomatis. The technology leverages the bacterium Salmonella Typhi Ty21a which has been engineered to express and secrete two coronavirus antigens fused to an immunological adjuvant peptide. The specific bacterial vector strain is being designed with the goal to enable oral application and release of the proteins into the gut system to stimulate (through M-cells) mucosal and systemic immunity.

Potential to be
temperature stable
, the marketed Salmonella Typhi vaccine is stable at 2°C – 8°C*

Salmonella Typhi Ty21a carrier strain has been safely used in more than 150 million administered doses worldwide

Developed at leading research and teaching university,
Julius-Maximilians-University Wuerzburg

* Vivotif™; Package Insert USA, April 2017

Oral COVID-19 (SARS-CoV-2) Vaccine

Currently undergoing pre-clinical studies for the prevention of coronavirus diseases, including COVID-19 (SARS-CoV-2)

  • Potential to induce mucosal immunity to prevent infection and avoid transmission

  • Higher likelihood for improved defense against mutated virus variants if not only spike protein is used as antigen

Chlamydia trachomatis Vaccine

Sexually transmitted gram-negative bacterium infecting over 130 million people annually (WHO, 2012)

  • Asymptomatic disease can spread to the reproductive tract inducing infertility, miscarriage, or ectopic pregnancy, which is a life-threatening condition

  • Ocular infections can lead to inclusion conjunctivitis or trachoma, which is the primary source of visual impairment or infectious blindness